Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Rudd who wrote (77539)	10/27/2025 8:27:42 AM
From: E_K_S	Read Replies (2) of 78412

Organon (NYSE: OGN) -20% - Shares plunged after CEO Kevin Ali resigned amid an audit committee investigation into improper wholesaler sales practices involving the contraceptive Nexplanon, where U.S. wholesalers were encouraged to buy excess inventory across multiple quarters from 2022 to 2025. While the sales involved represented less than 1% of revenue, the practice helped Organon meet revenue guidance and external expectations. Joseph Morrissey, EVP and head of manufacturing & supply, has been named interim CEO, with board chair Carrie Cox stepping in as executive chair and Robert Essner becoming lead independent director. The company has terminated its Head of U.S. Commercial & Government Affairs, is strengthening financial controls, and has begun searching for a permanent CEO; the probe did not find CFO involvement ------------------------------------------------------- Will be adding at the Open OGN -20.31%

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next